Efficacy of zonisamide in Lafora's disease case and brief review of its use in progressive myoclonic epilepsy

Mioclonic progressive epilepsy (MPE) includes a clinical and genetical heterogeneous group of neuro-degenerative disorders that associate spontaneous and action-induced myoclonus as well as progressive cognitive impairment. Lafora`s disease is a subtype of MPE with autosomical recessive inheritance...

Full description

Saved in:
Bibliographic Details
Published in:Revista de neurologiá 2022-09, Vol.75 (6), p.159-163
Main Authors: Rubio-Nazábal, E, Álvarez-Pérez, P, Cores-Bartolomé, C, Lema-Facal, T
Format: Article
Language:Spanish
Subjects:
Anticonvulsants - therapeutic use
Humans
Lafora Disease - diagnosis
Lafora Disease - drug therapy
Lafora Disease - genetics
Myoclonic Epilepsies, Progressive - drug therapy
Myoclonic Epilepsies, Progressive - genetics
Myoclonus
Zonisamide - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mioclonic progressive epilepsy (MPE) includes a clinical and genetical heterogeneous group of neuro-degenerative disorders that associate spontaneous and action-induced myoclonus as well as progressive cognitive impairment. Lafora`s disease is a subtype of MPE with autosomical recessive inheritance due to a mutation in EPM2A or EPM2B genes. Seizures, especially myoclonus, are often refractary to antiepileptic drugs (AD). In this article we report a patient with Lafora´s disease diagnosis, previously resistant to several AD tested with good and sustained response to zonisamide. Indeed, we describe a brief review about the efficacy of zonisamida in MPE. Zonisamide may be considered as a good therapeutic alternative in MPE.
ISSN:1576-6578
DOI:10.33588/rn.7506.2021397